CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 403 enrolled
Drug / intervention
Nicotine polacrilex, Bupropiondrug
Likely dose
Bupropion for 12 weeks and nicotine replacement for 10 weeksAI-extracted
Key inclusion· 1
  • ✓Current smoker of at least 10 cigarettes per day
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00086385
NCT00086385Phase 3Completed
CompareCT.gov

Maintaining Nonsmoking: Older Smokers

University of California, San Francisco·interventional·Posted Jul 7, 2004·Updated Mar 23, 2015

In Brief

A Phase 3 clinical trial evaluating Nicotine polacrilex, Bupropion for Tobacco Use Disorder. Completed, enrolled 403 participants across 1 site.

Detailed Summary

The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 7, 2004
Enrollment StartSep 1, 2001
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 22.0 years ago

Interventions

Nicotine polacrilex, Bupropiondrug

Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.